[New immune suppressants: topical immunomodulatory agents].
Chronic antiinflammatory treatment is required in autoimmunologic dermatoses. Tacrolimus ointment (Protopic) an inhibitor of calcineurin, is the first topical nonsteroidal immunosuppressant for the last 50 years. Pimecrolimus (ASM 981), a newer calcineurin inhibitor developed for atopic dermatitis treatment has the same mode of action and altered skin penetration profile as takrolimus. Their structure, mechanism of immunosuppressive action, efficacy and safety in atopic dermatitis and other inflammatory dermatitides was described in this article. The attention was paid to systemic and in topical treatment, their intact and injured skin penetration profile, optimal doses, costs and perspectives of broad use of these drugs in dermatology were described.
Senatorski
Grzegorz
G
Klinika Immunologii, Transplantologii i Chorób Wewnetrznych, Instytut Transplantologii Akademii Medycznej w Warszawie.
Sułowicz
Władysław
W
Paczek
Leszek
L
D000287:Administration, Topical; D065095:Calcineurin Inhibitors; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D009824:Ointments; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus
Nowe leki immunosupresyjne: leki immunomodulujace do stosowania zewnetrznego.